000126647 001__ 126647
000126647 005__ 20240228140838.0
000126647 0247_ $$2doi$$a10.1007/s00066-014-0740-z
000126647 0247_ $$2pmid$$apmid:25156510
000126647 0247_ $$2ISSN$$a0039-2073
000126647 0247_ $$2ISSN$$a0179-7158
000126647 0247_ $$2ISSN$$a1439-099X
000126647 037__ $$aDKFZ-2017-02675
000126647 041__ $$aeng
000126647 082__ $$a610
000126647 1001_ $$aHäfner, Matthias Felix$$b0
000126647 245__ $$aPostoperative radiotherapy of patients with thymic epithelial tumors (TET): a retrospective analysis of outcome and toxicity.
000126647 260__ $$aHeidelberg$$bSpringer51814$$c2015
000126647 264_1 $$2Crossref$$3online$$bSpringer Science and Business Media LLC$$c2014-08-26
000126647 264_1 $$2Crossref$$3print$$bSpringer Science and Business Media LLC$$c2015-02-01
000126647 264_1 $$2Crossref$$3print$$bSpringer Science and Business Media LLC$$c2015-02-01
000126647 3367_ $$2DRIVER$$aarticle
000126647 3367_ $$2DataCite$$aOutput Types/Journal article
000126647 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1522152040_18537
000126647 3367_ $$2BibTeX$$aARTICLE
000126647 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000126647 3367_ $$00$$2EndNote$$aJournal Article
000126647 520__ $$aThe purpose of this study was to evaluate postoperative radiotherapy regarding outcome and toxicity in patients with thymic epithelial tumors (TET) after surgery.We retrospectively analyzed medical records of 41 patients with TET treated with postoperative radiotherapy at our institution between 1995 and 2012. The impact of prognostic factors (e.g., Masaoka stage, histological subtype) was investigated and radiation-related toxicity was assessed.Median age was 59.8 years and median follow-up was 61 months. In 24.4 %, TETs were associated with paraneoplastic syndromes. The 5-year overall survival (OS) was 89.5 % and the 5-year disease-free survival (DFS) was 88.9 %. Masaoka stage had a significant impact on OS (p = 0.007). Locally limited stages I + II had a 5-year OS of 100 % compared to 80 % for stage III and 66.7 % for stage IV. The 5-year DFS was excellent with 100 % for both WHO groups A/AB/B1 and B2, respectively, and significantly (p = 0.005) differed from B3/C-staged patients with a 5-year DFS of 63.6 %. Resection status, paraneoplastic association, radiation dose, or tumor size did not influence survival. There were no high-grade acute or late side effects caused by radiotherapy.Masaoka stage has a significant impact on OS as WHO type has on DFS in patients with TETs after surgery and adjuvant irradiation. Postoperative radiotherapy with doses around 50 Gy is safe and not likely to cause high-grade toxicity. Further prospective trials are necessary to separate patient subgroups that benefit from radiotherapy from those that do not.
000126647 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000126647 542__ $$2Crossref$$i2014-08-26$$uhttp://www.springer.com/tdm
000126647 588__ $$aDataset connected to CrossRef, PubMed,
000126647 7001_ $$0P:(DE-HGF)0$$aRoeder, Falk$$b1
000126647 7001_ $$0P:(DE-He78)75d45845a04db67c5a88db1086046ef1$$aSterzing, Florian$$b2$$udkfz
000126647 7001_ $$aKrug, David$$b3
000126647 7001_ $$aKoerber, Stefan A$$b4
000126647 7001_ $$aKappes, Jutta$$b5
000126647 7001_ $$aHoffmann, Hans$$b6
000126647 7001_ $$0P:(DE-He78)4169c43af2de6fae487c89fc2e7cfaa8$$aSlynko, Alla$$b7$$udkfz
000126647 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, Jürgen$$b8$$udkfz
000126647 7001_ $$aBischof, Marc$$b9
000126647 77318 $$2Crossref$$3journal-article$$a10.1007/s00066-014-0740-z$$bSpringer Science and Business Media LLC$$d2014-08-26$$n2$$p133-140$$tStrahlentherapie und Onkologie$$v191$$x0179-7158$$y2014
000126647 773__ $$0PERI:(DE-600)2003907-4$$a10.1007/s00066-014-0740-z$$gVol. 191, no. 2, p. 133 - 140$$n2$$p133-140$$tStrahlentherapie und Onkologie$$v191$$x0179-7158$$y2014
000126647 909CO $$ooai:inrepo02.dkfz.de:126647$$pVDB
000126647 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000126647 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)75d45845a04db67c5a88db1086046ef1$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000126647 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4169c43af2de6fae487c89fc2e7cfaa8$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000126647 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000126647 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000126647 9141_ $$y2015
000126647 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000126647 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000126647 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bSTRAHLENTHER ONKOL : 2015
000126647 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000126647 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000126647 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000126647 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000126647 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000126647 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000126647 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000126647 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000126647 9201_ $$0I:(DE-He78)E055-20160331$$kE055$$lMolekulare Radioonkologie$$x0
000126647 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lKKE Strahlentherapie$$x1
000126647 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x2
000126647 980__ $$ajournal
000126647 980__ $$aVDB
000126647 980__ $$aI:(DE-He78)E055-20160331
000126647 980__ $$aI:(DE-He78)E050-20160331
000126647 980__ $$aI:(DE-He78)C060-20160331
000126647 980__ $$aUNRESTRICTED
000126647 999C5 $$1EA Engels$$2Crossref$$9-- missing cx lookup --$$a10.1002/ijc.11099$$p546 -$$tInt J Cancer$$uEngels EA, Pfeiffer RM (2003) Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies. Int J Cancer 105:546–551$$v105$$y2003
000126647 999C5 $$1YD Chen$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.ijrobp.2009.09.066$$p1400 -$$tInt J Radiat Oncol Biol Phys$$uChen YD, Feng QF, Lu HZ et al (2010) Role of adjuvant radiotherapy for stage II thymoma after complete tumor resection. Int J Radiat Oncol Biol Phys 78:1400–1406$$v78$$y2010
000126647 999C5 $$1G Zhu$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.ijrobp.2004.05.013$$p1113 -$$tInt J Radiat Oncol Biol Phys$$uZhu G, He S, Fu X et al (2004) Radiotherapy and prognostic factors for thymoma: a retrospective study of 175 patients. Int J Radiat Oncol Biol Phys 60:1113–1119$$v60$$y2004
000126647 999C5 $$1K Kondo$$2Crossref$$9-- missing cx lookup --$$a10.1016/S0003-4975(03)00555-1$$p878 -$$tAnn Thorac Surg$$uKondo K, Monden Y (2003) Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan. Ann Thorac Surg 76:878–884 (discussion 884–875)$$v76$$y2003
000126647 999C5 $$1WJ Curran Jr$$2Crossref$$9-- missing cx lookup --$$a10.1200/JCO.1988.6.11.1722$$p1722 -$$tJ Clin Oncol$$uCurran WJ Jr, Kornstein MJ, Brooks JJ et al (1988) Invasive thymoma: the role of mediastinal irradiation following complete or incomplete surgical resection. J Clin Oncol 6:1722–1727$$v6$$y1988
000126647 999C5 $$1JA Forquer$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.ijrobp.2009.02.016$$p440 -$$tInt J Radiat Oncol Biol Phys$$uForquer JA, Rong N, Fakiris AJ et al (2010) Postoperative radiotherapy after surgical resection of thymoma: differing roles in localized and regional disease. Int J Radiat Oncol Biol Phys 76:440–445$$v76$$y2010
000126647 999C5 $$1CD Fuller$$2Crossref$$9-- missing cx lookup --$$a10.1097/JTO.0b013e3181f20ec4$$p327 -$$tJ Thorac Oncol$$uFuller CD, Ramahi EH, Aherne N et al (2010) Radiotherapy for thymic neoplasms. J Thorac Oncol 5:S 327–335$$v5$$y2010
000126647 999C5 $$1RJ Korst$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.athoracsur.2008.11.022$$p1641 -$$tAnn Thorac Surg$$uKorst RJ, Kansler AL, Christos PJ et al (2009) Adjuvant radiotherapy for thymic epithelial tumors: a systematic review and meta-analysis. Ann Thorac Surg 87:1641–1647$$v87$$y2009
000126647 999C5 $$1A Masaoka$$2Crossref$$9-- missing cx lookup --$$a10.1002/1097-0142(19811201)48:11<2485::AID-CNCR2820481123>3.0.CO;2-R$$p2485 -$$tCancer$$uMasaoka A, Monden Y, Nakahara K et al (1981) Follow-up study of thymomas with special reference to their clinical stages. Cancer 48:2485–2492$$v48$$y1981
000126647 999C5 $$1A Masaoka$$2Crossref$$9-- missing cx lookup --$$a10.1016/1010-7940(94)90155-4$$p251 -$$tEur J Cardiothorac Surg$$uMasaoka A, Yamakawa Y, Niwa H et al (1994) Thymectomy and malignancy. Eur J Cardiothorac Surg 8:251–253$$v8$$y1994
000126647 999C5 $$1J Rosai$$2Crossref$$9-- missing cx lookup --$$a10.1007/978-3-642-60157-6$$uRosai J (1999) Histological typing of tumours of the thymus. Springer, New York$$y1999
000126647 999C5 $$1P Strobel$$2Crossref$$9-- missing cx lookup --$$a10.1007/s00595-005-3047-y$$p805 -$$tSurg Today$$uStrobel P, Marx A, Zettl A et al (2005) Thymoma and thymic carcinoma: an update of the WHO Classification 2004. Surg Today 35:805–811$$v35$$y2005
000126647 999C5 $$1GD Levine$$2Crossref$$9-- missing cx lookup --$$a10.1016/S0046-8177(78)80131-2$$p495 -$$tHum Pathol$$uLevine GD, Rosai J (1978) Thymic hyperplasia and neoplasia: a review of current concepts. Hum Pathol 9:495–515$$v9$$y1978
000126647 999C5 $$1AM Marchevsky$$2Crossref$$9-- missing cx lookup --$$a10.1002/cncr.23492$$p2780 -$$tCancer$$uMarchevsky AM, Gupta R, Mckenna RJ et al (2008) Evidence-based pathology and the pathologic evaluation of thymomas: the World Health Organization classification can be simplified into only 3 categories other than thymic carcinoma. Cancer 112:2780–2788$$v112$$y2008
000126647 999C5 $$1KL Wu$$2Crossref$$9-- missing cx lookup --$$a10.3109/07357900802563002$$p1008 -$$tCancer Invest$$uWu KL, Mao JF, Chen GY et al (2009) Prognostic predictors and long-term outcome of postoperative irradiation in thymoma: a study of 241 patients. Cancer Invest 27:1008–1015$$v27$$y2009
000126647 999C5 $$1S Patel$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.ijrobp.2011.03.010$$p1797 -$$tInt J Radiat Oncol Biol Phys$$uPatel S, Macdonald OK, Nagda S et al (2012) Evaluation of the role of radiation therapy in the management of malignant thymoma. Int J Radiat Oncol Biol Phys 82:1797–1801$$v82$$y2012
000126647 999C5 $$1Y Kundel$$2Crossref$$9-- missing cx lookup --$$a10.1097/COC.0b013e318042d566$$p389 -$$tAm J Clin Oncol$$uKundel Y, Yellin A, Popovtzer A et al (2007) Adjuvant radiotherapy for thymic epithelial tumor: treatment results and prognostic factors. Am J Clin Oncol 30:389–394$$v30$$y2007
000126647 999C5 $$1JH Chang$$2Crossref$$9-- missing cx lookup --$$a10.1097/JTO.0b013e31821f9662$$p1282 -$$tJ Thorac Oncol$$uChang JH, Kim HJ, Wu HG et al (2011) Postoperative radiotherapy for completely resected stage II or III thymoma. J Thorac Oncol 6:1282–1286$$v6$$y2011
000126647 999C5 $$1T Harnath$$2Crossref$$9-- missing cx lookup --$$a10.1097/JTO.0b013e3182745f73$$p1867 -$$tJ Thorac Oncol$$uHarnath T, Marx A, Strobel P et al (2012) Thymoma—a clinico-pathological long-term study with emphasis on histology and adjuvant radiotherapy dose. J Thorac Oncol 7:1867–1871$$v7$$y2012
000126647 999C5 $$1K Ogawa$$2Crossref$$9-- missing cx lookup --$$a10.1002/cncr.10373$$p1405 -$$tCancer$$uOgawa K, Uno T, Toita T et al (2002) Postoperative radiotherapy for patients with completely resected thymoma: a multi-institutional, retrospective review of 103 patients. Cancer 94:1405–1413$$v94$$y2002
000126647 999C5 $$1P Strobel$$2Crossref$$9-- missing cx lookup --$$a10.1200/JCO.2004.10.113$$p1501 -$$tJ Clin Oncol$$uStrobel P, Bauer A, Puppe B et al (2004) Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis. J Clin Oncol 22:1501–1509$$v22$$y2004
000126647 999C5 $$1V Vassiliou$$2Crossref$$uVassiliou V, Tsamandas A, Katodritis N et al (2009) The role of postoperative radiotherapy in the management of patients with thymic tumors—a retrospective study. In Vivo 23:843–852$$y2009
000126647 999C5 $$1S Singhal$$2Crossref$$9-- missing cx lookup --$$a10.1016/S0003-4975(03)00819-1$$p1635 -$$tAnn Thorac Surg$$uSinghal S, Shrager JB, Rosenthal DI et al (2003) Comparison of stages I–II thymoma treated by complete resection with or without adjuvant radiation. Ann Thorac Surg 76:1635–1641 (discussion 1641–1632)$$v76$$y2003
000126647 999C5 $$1AT Berman$$2Crossref$$9-- missing cx lookup --$$a10.1002/cncr.25851$$p3502 -$$tCancer$$uBerman AT, Litzky L, Livolsi V et al (2011) Adjuvant radiotherapy for completely resected stage 2 thymoma. Cancer 117:3502–3508$$v117$$y2011
000126647 999C5 $$1AA Mangi$$2Crossref$$9-- missing cx lookup --$$a10.1016/S0003-4975(02)03828-6$$p1033 -$$tAnn Thorac Surg$$uMangi AA, Wright CD, Allan JS et al (2002) Adjuvant radiation therapy for stage II thymoma. Ann Thorac Surg 74:1033–1037$$v74$$y2002
000126647 999C5 $$1C Fan$$2Crossref$$9-- missing cx lookup --$$a10.1186/1748-717X-8-199$$p199 -$$tRadiat Oncol$$uFan C, Feng Q, Chen Y et al (2013) Postoperative radiotherapy for completely resected Masaoka stage III thymoma: a retrospective study of 65 cases from a single institution. Radiat Oncol 8:199$$v8$$y2013
000126647 999C5 $$1B Weksler$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.athoracsur.2012.03.004$$p1822 -$$tAnn Thorac Surg$$uWeksler B, Shende M, Nason KS et al (2012) The role of adjuvant radiation therapy for resected stage III thymoma: a population-based study. Ann Thorac Surg 93:1822–1828 (discussion 1828–1829)$$v93$$y2012
000126647 999C5 $$1AA Mangi$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.athoracsur.2004.12.051$$p1834 -$$tAnn Thorac Surg$$uMangi AA, Wain JC, Donahue DM et al (2005) Adjuvant radiation of stage III thymoma: is it necessary? Ann Thorac Surg 79:1834–1839$$v79$$y2005
000126647 999C5 $$1M Myojin$$2Crossref$$9-- missing cx lookup --$$a10.1016/S0360-3016(99)00514-3$$p927 -$$tInt J Radiat Oncol Biol Phys$$uMyojin M, Choi NC, Wright CD et al (2000) Stage III thymoma: pattern of failure after surgery and postoperative radiotherapy and its implication for future study. Int J Radiat Oncol Biol Phys 46:927–933$$v46$$y2000
000126647 999C5 $$1R Sauer$$2Crossref$$9-- missing cx lookup --$$a10.1056/NEJMoa040694$$p1731 -$$tN Engl J Med$$uSauer R, Becker H, Hohenberger W et al (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731–1740$$v351$$y2004
000126647 999C5 $$1FA Calvo$$2Crossref$$9-- missing cx lookup --$$a10.1007/s00066-013-0469-0$$p149 -$$tStrahlenther Onkol$$uCalvo FA, Sole CV, Serrano J et al (2014) Preoperative chemoradiation with or without induction oxaliplatin plus 5-fluorouracil in locally advanced rectal cancer: long-term outcome analysis. Strahlenther Onkol 190:149–157$$v190$$y2014
000126647 999C5 $$1H Kunitoh$$2Crossref$$9-- missing cx lookup --$$a10.1038/sj.bjc.6605731$$p6 -$$tBr J Cancer$$uKunitoh H, Tamura T, Shibata T et al (2010) A phase II trial of dose-dense chemotherapy, followed by surgical resection and/or thoracic radiotherapy, in locally advanced thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9606). Br J Cancer 103:6–11$$v103$$y2010
000126647 999C5 $$1RJ Korst$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.jtcvs.2013.08.061$$p36 -$$tJ Thorac Cardiovasc Surg$$uKorst RJ, Bezjak A, Blackmon S et al (2014) Neoadjuvant chemoradiotherapy for locally advanced thymic tumors: a phase II, multi-institutional clinical trial. J Thorac Cardiovasc Surg 147:36–44, 46 (e1)$$v147$$y2014
000126647 999C5 $$1HC Hsu$$2Crossref$$9-- missing cx lookup --$$a10.1016/S0360-3016(01)02656-6$$p801 -$$tInt J Radiat Oncol Biol Phys$$uHsu HC, Huang EY, Wang CJ et al (2002) Postoperative radiotherapy in thymic carcinoma: treatment results and prognostic factors. Int J Radiat Oncol Biol Phys 52:801–805$$v52$$y2002
000126647 999C5 $$1TY Eng$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.ijrobp.2003.11.021$$p654 -$$tInt J Radiat Oncol Biol Phys$$uEng TY, Fuller CD, Jagirdar J et al (2004) Thymic carcinoma: state of the art review. Int J Radiat Oncol Biol Phys 59:654–664$$v59$$y2004
000126647 999C5 $$1LM Tormoehlen$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.hoc.2008.03.004$$p509 -$$tHematol Oncol Clin North Am$$uTormoehlen LM, Pascuzzi RM (2008) Thymoma, myasthenia gravis, and other paraneoplastic syndromes. Hematol Oncol Clin North Am 22:509–526$$v22$$y2008
000126647 999C5 $$1K Fakhrian$$2Crossref$$9-- missing cx lookup --$$a10.1007/s00066-012-0297-7$$p293 -$$tStrahlenther Onkol$$uFakhrian K, Oechsner M, Kampfer S et al (2013) Advanced techniques in neoadjuvant radiotherapy allow dose escalation without increased dose to the organs at risk: Planning study in esophageal carcinoma. Strahlenther Onkol 189:293–300$$v189$$y2013
000126647 999C5 $$1C Song$$2Crossref$$9-- missing cx lookup --$$a10.1007/s00066-012-0159-3$$p901 -$$tStrahlenther Onkol$$uSong C, Pyo H, Kim J et al (2012) Superiority of conventional intensity-modulated radiotherapy over helical tomotherapy in locally advanced non-small cell lung cancer. A comparative plan analysis. Strahlenther Onkol 188:901–909$$v188$$y2012
000126647 999C5 $$1R Butof$$2Crossref$$9-- missing cx lookup --$$a10.1007/s00066-013-0501-4$$p263 -$$tStrahlenther Onkol$$uButof R, Kirchner K, Appold S et al (2014) Potential clinical predictors of outcome after postoperative radiotherapy of non-small cell lung cancer. Strahlenther Onkol 190:263–269$$v190$$y2014
000126647 999C5 $$1D Latz$$2Crossref$$9-- missing cx lookup --$$a10.1148/radiology.204.3.9280272$$p859 -$$tRadiology$$uLatz D, Schraube P, Oppitz U et al (1997) Invasive thymoma: treatment with postoperative radiation therapy. Radiology 204:859–864$$v204$$y1997